Rifaximin systemic absorption in patients with ulcerative colitis [1]

European Journal of Clinical Pharmacology

Volumn 54, Issue 1, 1998, Pages 91-93

  Rizzello, F ^b   Gionchetti, P ^b   Venturi, A ^b   Ferretti, M ^b   Peruzzo, S ^b   Raspanti, X ^b   Picard, M ^c   Canova, N ^a   Palazzini, E ^a   Campieri, M ^b  

^a Alfa Wassermann SpA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Larime SA Lab Rech l'I   (France)

Author keywords

Rifaximin; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; MESALAZINE; METHYLPREDNISOLONE; RIFAXIMIN;

ADULT; AGED; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BILIARY EXCRETION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; LETTER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ABSORPTION; ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; RIFAMYCINS;

EID: 7144263705     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050426     Document Type: Letter

References (14)

1. Sartor RB (1990) Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 4: 271-277
2. Chadwick VS, Anderson RP (1992) Microganisms and their products in inflammatory bowel disease. In: Mac Dermott RP, Stenson WF (eds.) Inflammatory bowel disease. Elsevier, New York, pp 241-258
3. Venturini AP, Marchi E (1986) In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 5: 257-262
4. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfeller MA, Jones RM (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 16: 111-118
5. Descombe JJ, Dubourg D, Picard M, Palazzini E (1994) Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 14: 51-56
6. Gillis JC, Brogden RN (1995) Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49: 467-484
7. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M (1997) Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind placebo controlled trial. Dig Dis Sci, (In press)
8. Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 2: 1041-1048
9. Baron JH, Connel AM, Lennard-Jones JE (1964) Variation between observers in describing mucosal appearances in protocolitis. Br Med J 1: 89-92
10. Verardi S, Verardi V (1990) Bile rifaximin concentration after oral administration in patients undergoing cholecistectomy. Farmaco Prat 45: 131-135
11. Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27: 1210-1212
12. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon ATR (1985) Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26: 1380-1384
13. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G (1994) Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1: 43-46
14. Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4: 123-130